![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1308, 2001-01, pp. : 16-16
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infliximab promising in paediatric Crohn's disease
Inpharma, Vol. 1, Iss. 1391, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infliximab: additional benefits in Crohn's disease
Inpharma, Vol. 1, Iss. 1349, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infliximab worth it for Crohn's disease in the UK
Inpharma, Vol. 1, Iss. 1515, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Emerging drugs to treat Crohn's disease
By Strauch Ulrike Schölmerich Jürgen
Expert Opinion on Emerging Drugs, Vol. 15, Iss. 2, 2010-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tamoxifen was used successfully to treat retroperitoneal fibrosis
Inpharma, Vol. 1, Iss. 1358, 2002-01 ,pp. :